Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Positively Aware : the Monthly Journal of the Test Positive Aware Network
|
May 8, 2013
Timing and T-cells
Howard A Grossman
The AIDS Reader
|
October 10, 2006
Addressing the need for HIV specialists: the AAHIVM perspective
Howard A Grossman
The AIDS Reader
|
February 13, 2004
Quality of life and HIV: current assessment tools and future directions for clinical practice
Howard A Grossman, Patrick S Sullivan, Albert W Wu
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 15, 2003
Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients
Howard A Grossman, Betty Goon, Peter Bowers, et al.
AIDS (London, England)
|
December 31, 2008
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial
Calvin J Cohen, Daniel S Berger, Gary Blick, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Positively Aware : the Monthly Journal of the Test Positive Aware Network
|
May 8, 2013
Timing and T-cells
Howard A Grossman
The AIDS Reader
|
October 10, 2006
Addressing the need for HIV specialists: the AAHIVM perspective
Howard A Grossman
The AIDS Reader
|
February 13, 2004
Quality of life and HIV: current assessment tools and future directions for clinical practice
Howard A Grossman, Patrick S Sullivan, Albert W Wu
Journal of Acquired Immune Deficiency Syndromes (1999)
|
November 15, 2003
Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients
Howard A Grossman, Betty Goon, Peter Bowers, et al.
AIDS (London, England)
|
December 31, 2008
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial
Calvin J Cohen, Daniel S Berger, Gary Blick, et al.
Page
of 1